Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 25, 2024
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
Miriam Blasi, Jonas Kuon, Heike Lüders, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Marcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Journal of Neuro-Oncology
|
December 4, 2024
TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression
David Wasilewski, Tommaso Araceli, Philip Bischoff, et al.
Virchows Archiv : an International Journal of Pathology
|
October 8, 2024
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities
Katharina Möller, Tayyaba Gulzar, Maximilian Lennartz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Philip Bischoff, Martin Reck, Tobias Overbeck, et al.
Journal of Neuro-Oncology
|
February 11, 2025
Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry
David Wasilewski, Chiara Eitner, Rober Ates, et al.
Nature Communications
|
November 3, 2025
AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer
Simon Schallenberg, Gabriel Dernbach, Sharon Ruane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
ADC target profiling in NSCLC: Generalizable AI separates TROP-2 and cMET phenotypes
Philipp Anders, Marvin Sextro, Katja Lingelbach, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Jan A Stratmann, Friederike C Althoff, Paula Doebel, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
Lung Cancer (Amsterdam, Netherlands)
|
August 8, 2025
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 25, 2024
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations
Miriam Blasi, Jonas Kuon, Heike Lüders, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Marcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
Journal of Neuro-Oncology
|
December 4, 2024
TTF-1 negativity in synchronous M1b/M1c wildtype lung adenocarcinoma brain metastases predicts worse survival with increased risk of intracranial progression
David Wasilewski, Tommaso Araceli, Philip Bischoff, et al.
Virchows Archiv : an International Journal of Pathology
|
October 8, 2024
TTF-1 is a highly sensitive but not fully specific marker for pulmonary and thyroidal cancer: a tissue microarray study evaluating more than 17,000 tumors from 152 different tumor entities
Katharina Möller, Tayyaba Gulzar, Maximilian Lennartz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer
Philip Bischoff, Martin Reck, Tobias Overbeck, et al.
Journal of Neuro-Oncology
|
February 11, 2025
Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry
David Wasilewski, Chiara Eitner, Rober Ates, et al.
Nature Communications
|
November 3, 2025
AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer
Simon Schallenberg, Gabriel Dernbach, Sharon Ruane, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
ADC target profiling in NSCLC: Generalizable AI separates TROP-2 and cMET phenotypes
Philipp Anders, Marvin Sextro, Katja Lingelbach, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
Jan A Stratmann, Friederike C Althoff, Paula Doebel, et al.
Page
of 7